Biotech · Private company
Kamada, Ltd.
Track this companyFree. Adds Kamada, Ltd. to your Dealase workspace and tells you when its record changes.
Clinical trials62 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- Active rabies vaccine (US-FDA approved)Phase 3 · RabiesClinicalTrials.gov · fetched Nov 12, 2026
- KamRAB - HRIGPhase 3 · RabiesClinicalTrials.gov · fetched Nov 12, 2026
- Kamada-AAT for Inhalation, 160mgPhase 2 · Alpha-1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
- Kamada-AAT for Inhalation, 80mgPhase 2 · Alpha-1 Antitrypsin DeficiencyClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Strategic Help With Immunoglobulin to Enhance Protect Against Late Disease (CMV)PHASE4 · RECRUITING · started Nov 27, 2025ClinicalTrials.gov NCT06958796 · fetched Nov 12, 2026
- CytoGam for CMV Infection or Disease in Solid Organ Transplant RecipientsPHASE4 · ENROLLING_BY_INVITATION · started Jun 26, 2025ClinicalTrials.gov NCT07009548 · fetched Nov 12, 2026
- A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHDPHASE2_PHASE3 · TERMINATED · started Apr 26, 2017ClinicalTrials.gov NCT02956122 · fetched Nov 12, 2026
- Post-marketing Study of KamRAB Administered as a Single Dose With Active Rabies Vaccine in Children Exposed to RabiesPHASE3 · COMPLETED · started Aug 1, 2016ClinicalTrials.gov NCT02912845 · fetched Nov 12, 2026
- Phase II, Safety and Efficacy Study of Kamada-alpha-1-antitrypsin (AAT) for Inhalation"PHASE2 · COMPLETED · started Apr 1, 2014ClinicalTrials.gov NCT02001688 · fetched Nov 12, 2026
- Phase II/III Study of the Safety and Effectiveness of HRIG With Active Rabies Vaccine in Healthy SubjectsPHASE2_PHASE3 · COMPLETED · started Apr 1, 2013ClinicalTrials.gov NCT02040090 · fetched Nov 12, 2026